COSCIENS BIOPHARMA INC(NASDAQ:CSCI) stock News

CSCI Latest News, Press Relases and Analysis

All

Press Releases

26 days ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

2 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

2 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

2 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

a year ago - By: InvestorPlace

CSCI Stock Earnings: AEterna Zentaris Beats Revenue for Q2 2024

a year ago - By: BusinessInsider

CSCI Stock Earnings: AEterna Zentaris Beats Revenue for Q2 2024

3 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

4 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

4 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

4 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

5 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

7 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

9 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

10 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Announces Change to Board of Directors

10 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

10 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

a year ago - By: Benzinga - Mentions: AMWD VOXX AAMC ADXN ...

S&P 500 Edges Higher; American Woodmark Shares Slide

a year ago - By: Benzinga - Mentions: AMWD HAIN VOXX AAMC ...

Crude Oil Dips; Addex Therapeutics Shares Spike Higher

a year ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

a year ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI.CA

COSCIENS BIOPHARMA INC (CSCI) Stock News

CSCI Latest News, Press Relases and Analysis

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

CSCI Stock Earnings: AEterna Zentaris Beats Revenue for Q2 2024

CSCI Stock Earnings: AEterna Zentaris Beats Revenue for Q2 2024

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

COSCIENS Biopharma Announces Change to Board of Directors

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

S&P 500 Edges Higher; American Woodmark Shares Slide

Crude Oil Dips; Addex Therapeutics Shares Spike Higher

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results